Financial Performance - Revenue for Q3 2022 reached ¥604,530,846.87, an increase of 55.15% compared to the same period last year[3] - Net profit attributable to shareholders was ¥401,221,323.49, reflecting a growth of 41.55% year-over-year[3] - The net profit excluding non-recurring gains and losses was ¥394,649,752.93, up 52.26% from the previous year[3] - Basic earnings per share for the quarter were ¥1.85, representing a 41.22% increase compared to the same period last year[3] - The net profit for the third quarter of 2022 reached ¥992,015,501.18, representing a 40.03% increase compared to ¥708,448,215.30 in the same period last year[10] - Total profit for the period was ¥1,159,819,361.46, a 39.54% increase from ¥831,172,090.87 in the previous year[10] - The company’s operating profit was ¥1,159,751,558.45, reflecting a 38.74% increase from ¥835,923,433.92 in the previous year[10] - The company’s total comprehensive income for Q3 2022 was ¥976,952,408.08, compared to ¥708,448,215.30 in Q3 2021, reflecting an increase of approximately 37.9%[21] Revenue and Sales - The company’s total revenue for the first nine months of 2022 was ¥1,489,444,489.63, a 45.58% increase from the same period in 2021[9] - Total operating revenue for Q3 2022 reached ¥1,489,444,489.63, a significant increase from ¥1,023,097,508.89 in the same period last year, representing a growth of approximately 45.5%[19] - Total revenue from sales of goods and services received cash of ¥1,481,868,638.32, up 44.26% from ¥1,027,185,645.09 year-on-year[10] - The company reported a significant increase in sales revenue from customer deposits and interbank placements, totaling ¥1,481,868,638.32, compared to ¥1,027,185,645.09 in the same period last year, representing a growth of about 44.0%[22] Assets and Liabilities - Total assets as of September 30, 2022, amounted to ¥5,832,916,258.02, a 10.79% increase from the end of the previous year[3] - Current assets totaled CNY 4,174,294,894.69, up from CNY 3,803,250,270.79 at the start of the year, reflecting a growth of approximately 9.8%[17] - Total liabilities were CNY 249,110,059.14, compared to CNY 235,175,026.70 at the beginning of the year, indicating a rise of about 5.5%[18] - The company's equity attributable to shareholders reached CNY 5,552,804,770.47, up from CNY 5,029,472,729.96, reflecting an increase of approximately 10.4%[18] Cash Flow - The company reported a significant increase in cash flow from operating activities, totaling ¥949,361,462.07, up 41.30% year-over-year[3] - The company reported a net cash flow from operating activities of ¥949,361,462.07, compared to ¥671,892,622.78 in the same quarter last year, marking an increase of around 41.3%[23] - Cash inflow from investment activities totaled ¥2,405,434,768.24, significantly higher than ¥655,016,000.70 in Q3 2021, showing a growth of approximately 267.5%[23] - The net cash flow from investment activities was -1,016,663,452.80 CNY, showing an improvement from -1,136,934,534.06 CNY in the previous period[24] - The net cash flow from financing activities was -441,000,570.62 CNY, an improvement from -462,791,975.00 CNY in the previous period[24] Research and Development - Research and development expenses for the first nine months of 2022 were ¥115,089,088.61, an increase of 86.66% compared to the same period in 2021[4] - Research and development expenses amounted to ¥115,089,088.61, up from ¥61,658,347.65 in the previous year, indicating a year-over-year increase of approximately 86.5%[19] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 33,204, with the largest shareholder holding 30.96% of the shares[12] - The company reported a total of 127,783,547 restricted shares at the end of the period, unchanged from the beginning of the year[15] - The company has plans to lift restrictions on certain shares on September 28, 2023, affecting several executives and investors[14]

Financial Performance - The company reported a significant increase in revenue for the first half of 2022, with total revenue reaching RMB 500 million, representing a year-on-year growth of 25%[7]. - The company achieved operating revenue of ¥884,913,642.76, a 39.70% increase compared to the same period last year[16]. - Net profit attributable to shareholders reached ¥590,970,770.75, reflecting a growth of 38.90% year-on-year[16]. - The net profit after deducting non-recurring gains and losses was ¥570,651,766.05, up 38.88% from the previous year[16]. - The company reported a total profit of CNY 689.33 million, an increase of 38.5% from CNY 497.80 million in the first half of 2021[120]. - The company achieved a net profit of CNY 590.97 million from continuing operations, a 39.0% increase from CNY 424.98 million in the same period last year[121]. - Basic and diluted earnings per share were both CNY 2.73, compared to CNY 1.97 in the same period of 2021, reflecting a 38.6% increase[121]. Revenue Guidance and Projections - The company has set a revenue guidance for the second half of 2022, projecting a growth rate of 20% year-on-year, aiming for a total revenue of RMB 600 million[7]. - Cash inflow from sales of goods and services was CNY 903,498,229.97, up from CNY 652,741,983.22, representing a growth of 38.3%[124]. Product Development and R&D - The company is investing in R&D, with a budget allocation of RMB 50 million for the development of innovative biocompatible materials[7]. - The R&D team comprises 25.41% of the total workforce, with approximately half holding master's degrees or higher, averaging over eight years of experience in the medical aesthetics field[37]. - Research and development expenses rose to ¥64,650,042.18, a 46.51% increase compared to the previous year, primarily due to higher salaries for R&D personnel and technical service fees[43]. - The company plans to continue investing in R&D to enhance product offerings and market expansion strategies[120]. Market Expansion and Strategy - Market expansion efforts are underway, targeting new regions in Southeast Asia, with an estimated market potential of RMB 200 million[7]. - The company has completed a strategic acquisition of a local competitor, enhancing its market share by 10%[7]. - The company is advancing its digital management initiatives, with information technology supporting various business processes[17]. - The company has established a diversified supplier system to mitigate supply chain risks and ensure stable production[17]. Online and Offline Initiatives - The company plans to enhance its online sales channels, aiming for a 30% increase in e-commerce revenue by the end of 2022[7]. - The company organized over 160 online and offline academic meetings during the reporting period, enhancing brand influence and increasing the number of registered doctors on its learning platform to over 12,000, with more than 30,000 users following[27]. - The company’s online learning platform, Quan Xuan Classroom, combines online and offline training to empower medical beauty practitioners and meet diverse consumer needs[27]. Financial Management and Investments - The company will not distribute cash dividends for the current fiscal year, focusing instead on reinvestment for growth[3]. - The company reported a significant increase in investment activities, with net cash flow from investing activities at -¥561,289,761.02, a decrease of 15,838.06% due to the purchase of financial products[44]. - The company has approved the use of up to 12 billion RMB of temporarily idle raised funds for cash management, investing in structured deposits and high-security financial products[58]. Risk Management - The company has identified potential risks, including regulatory changes, and has outlined measures to mitigate these risks in its management discussion[3]. - The company is actively responding to uncertainties caused by the COVID-19 pandemic by utilizing online marketing strategies, minimizing the impact on business operations[27]. - The tightening of industry regulations is expected to accelerate the expansion of the compliant product market, benefiting well-regulated midstream enterprises[28]. Shareholder Information - The largest shareholder, Jian Jun, holds 66,988,343 shares, accounting for 30.96% of total shares[104]. - The total number of common stock shareholders at the end of the reporting period was 37,291[104]. - The company has a total of 128,224,772 restricted shares before the change, which decreased to 127,783,547 after the adjustment[103]. Compliance and Regulatory Matters - The company has maintained 7 medical device registration certificates, consistent with the previous year, indicating stable regulatory compliance[29]. - The company has not faced any environmental penalties and has implemented measures to reduce pollution, including new wastewater treatment equipment[80]. Corporate Governance - The company appointed a new financial officer on January 7, 2022, to support its development needs[77]. - The financial report for the first half of 2022 was not audited[113]. - The company has not identified any significant doubts regarding its ability to continue as a going concern for the next 12 months[141].

Financial Performance - The company's revenue for Q1 2022 was CNY 430,712,581.75, representing a 66.07% increase compared to CNY 259,354,621.48 in the same period last year[3] - Net profit attributable to shareholders was CNY 280,095,605.38, up 64.03% from CNY 170,759,168.70 year-on-year[3] - Basic earnings per share increased to CNY 1.29, a rise of 63.29% compared to CNY 0.79 in the same period last year[3] - Total operating revenue for Q1 2022 reached CNY 430.71 million, a significant increase of 66.05% compared to CNY 259.35 million in Q1 2021[17] - Net profit for Q1 2022 was CNY 280.10 million, up 68.73% from CNY 165.82 million in the same period last year[18] - The total comprehensive income attributable to the parent company was CNY 275,786,603.22, compared to CNY 170,759,168.70 in the same period last year, reflecting an increase of approximately 61.5%[19] Cash Flow and Liquidity - The net cash flow from operating activities reached CNY 240,340,450.10, reflecting a 55.22% increase from CNY 154,835,447.05 in the previous year[3] - The company's cash and cash equivalents at the end of Q1 2022 amounted to ¥3,287,047,002.51, an increase from ¥3,263,543,715.87 at the beginning of the year[13] - The company has a strong focus on maintaining cash reserves while increasing trading financial assets, indicating a strategic approach to liquidity management[13] - Cash flow from operating activities generated a net amount of CNY 240,340,450.10, compared to CNY 154,835,447.05 in the previous year, indicating a year-over-year increase of 55.3%[22] - The cash and cash equivalents at the end of the period amounted to CNY 3,287,047,002.51, slightly down from CNY 3,291,463,280.43 at the end of the previous year[23] Assets and Liabilities - Total assets at the end of the reporting period were CNY 5,535,068,926.79, a 5.13% increase from CNY 5,264,825,778.13 at the end of the previous year[3] - The company’s total liabilities increased, with accounts payable rising by 91.98% to CNY 16,411,131.88 due to increased procurement activities[6] - Total liabilities decreased to CNY 229.49 million from CNY 235.18 million, a reduction of 2.93%[16] - Accounts receivable rose to CNY 81.28 million, compared to CNY 72.35 million, marking an increase of 12.68%[14] - Inventory increased slightly to CNY 35.30 million from CNY 34.94 million, a growth of 1.01%[14] Expenses - The company reported a significant increase in sales expenses, which rose by 94.59% to CNY 53,908,011.99 due to higher sales revenue[6] - Research and development expenses for Q1 2022 were CNY 29.06 million, up 24.36% from CNY 23.36 million in Q1 2021[18] - Sales expenses surged to CNY 53.91 million, an increase of 94.66% compared to CNY 27.70 million in the previous year[18] - The company paid CNY 464,125,275.50 for goods and services, which is an increase from CNY 276,983,214.65 in the same period last year, indicating a growth of 67.5%[22] Shareholder Information - The total number of common shareholders at the end of the reporting period was 43,655[9] - The largest shareholder, Jian Jun, holds 30.96% of the shares, totaling 66,988,343 shares[9] - The top ten shareholders collectively hold a significant portion of the company's shares, with the first two shareholders alone accounting for over 37%[9] - The company has a total of 128,224,772 restricted shares, with 441,225 shares released during the period[12] - The company plans to lift restrictions on certain shares on September 28, 2023, which may impact share liquidity[11] - The company has no preferred shareholders as per the report[10] - The report indicates no participation in margin trading by the top ten shareholders[10] Investment Activities - The company’s investment activities generated a net cash outflow of CNY 211,235,449.42, a significant decrease compared to the previous year due to increased purchases of financial products[7] - Total cash inflow from investment activities was CNY 743,125,643.82, up from CNY 472,877,630.55, marking a growth of 57.2%[22] - The company reported a net cash outflow from investment activities of CNY -211,235,449.42, compared to a net inflow of CNY 80,873,824.73 in the previous year[22] Profitability Metrics - The company’s net profit margin improved, driven by increased sales revenue and enhanced gross profit margin[7] - The company reported a gross profit margin of approximately 70.55% for Q1 2022, compared to 72.56% in Q1 2021[17] - The total equity attributable to shareholders increased to CNY 5.31 billion, up from CNY 5.03 billion, reflecting a growth of 5.36%[16] Audit and Compliance - The company did not conduct an audit for the first quarter report[24]

Dividend Distribution - The company plans to distribute a cash dividend of 35 RMB per 10 shares to all shareholders, based on a total share capital of 120,200,000 shares[4] - The total cash dividend distributed was CNY 420.70 million, accounting for 95.67% of the net profit attributable to the parent company for 2020[118] - The company plans to distribute a cash dividend of CNY 35 per 10 shares, totaling CNY 42.07 million[118] - The company has a strong and stable profitability outlook, which supports its dividend distribution strategy[118] Financial Performance - The company reported a net profit margin of 18% for the fiscal year 2020, reflecting strong operational efficiency[8] - The company's operating revenue for 2020 was ¥709,290,197, an increase of 27.18% compared to ¥557,715,652 in 2019[13] - Net profit attributable to shareholders for 2020 was ¥439,748,783.82, representing a 43.93% increase from ¥305,519,840.87 in 2019[13] - The net cash flow from operating activities for 2020 was ¥425,677,596.15, up 37.44% from ¥309,715,080.14 in 2019[13] - The company's total assets increased by 40% compared to the previous year, indicating robust financial health[8] - The company reported a total investment of ¥2,481,404,055.46 during the reporting period, a substantial increase of 194.49% compared to the previous year[74] Market Expansion and Strategy - The company is focusing on expanding its market presence, particularly in the Asia-Pacific region, aiming for a 15% market share by 2025[8] - The company anticipates a revenue growth of 30% for the next fiscal year, driven by new product launches and market expansion strategies[8] - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[8] - The company has established a sales service network covering all 31 provinces, municipalities, and autonomous regions in China[24] - The company is actively developing new medical beauty products, including injection products containing polylactic acid and botulinum toxin[22] Research and Development - The company has allocated 20 million RMB for research and development of new products and technologies in the upcoming fiscal year[8] - The company's R&D investment accounted for 8.71% of its operating revenue, with a year-on-year increase of 27.26%[31] - Research and development expenses increased by 27.26% to ¥61,804,030.84 in 2020, reflecting the company's commitment to innovation[58] - The company is investing in new technology development, allocating 150 million RMB towards R&D initiatives[200] Risk Management - The company has identified key risks in its future outlook, including regulatory changes and market competition, and has outlined strategies to mitigate these risks[3] - The company is aware of potential risks from the ongoing COVID-19 pandemic affecting its main clients, which are medical institutions, and will enhance online marketing efforts to mitigate impacts[107] - The company faces product development and registration risks due to the high-tech nature of the biomedical materials sector, which involves multiple regulatory approval stages[108] Product Development and Innovation - The company has successfully industrialized injection-type sodium hyaluronate products and face-implant lines during the reporting period[22] - The company has developed five differentiated sodium hyaluronate injection products, enhancing its market presence and brand influence[29] - New product launches included biodegradable materials and advanced facial implant technologies, which are expected to drive future sales[196] Shareholder Management - The company adheres to a clear cash dividend policy, ensuring that all shareholders' interests are protected through transparent decision-making processes[114] - The company has committed to fulfilling its promises regarding shareholding and capital management as of the report date[120] - The controlling shareholder must submit a specific plan for increasing their shareholding within 10 trading days if stock price stabilization measures are triggered[124] Sustainability Initiatives - The company is committed to sustainable practices and plans to invest in eco-friendly technologies, with a budget of 5 million RMB for sustainability initiatives[8] - The board of directors emphasized the importance of sustainability initiatives, committing to reduce carbon emissions by 25% over the next five years[192] Customer Engagement and Market Trends - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the fiscal year, representing a year-over-year growth of 25%[135] - User data showed a total of 10 million active users by the end of the reporting period, an increase of 15% compared to the previous year[138] - Customer satisfaction ratings improved to 90%, indicating strong brand loyalty and positive reception of new products[200]

Financial Performance - The company reported a significant increase in revenue, with a year-on-year growth rate of 30% in 2021 [8]. - The company's operating revenue for 2021 was ¥1,447,872,001.48, representing a 104.13% increase compared to ¥709,290,197.00 in 2020 [13]. - The net profit attributable to shareholders for 2021 was ¥957,798,548.01, a 117.81% increase from ¥439,748,783.82 in 2020 [13]. - The total profit for the year was 1,121.84 million CNY, with a year-on-year increase of 123.18% [25]. - The net profit reached 957.33 million CNY, reflecting a growth of 120.89% compared to the previous year [25]. - The company reported a net profit excluding non-recurring gains and losses of ¥914,421,058.03 for 2021, a 115.55% increase from ¥424,232,869.64 in 2020 [13]. - The company reported a basic earnings per share of ¥4.43, a decrease of 1.77% compared to ¥4.51 in 2020 [13]. - The company reported a significant increase in production and sales volumes across various product lines, driven by market expansion and improved product penetration [52]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the fiscal year, representing a 20% year-over-year growth [134]. Market Position and Strategy - The company is focusing on expanding its market presence, particularly in the medical aesthetics sector, which is projected to grow by 15% annually [8]. - The company operates in the medical beauty industry, focusing on the research, manufacturing, and commercialization of Class III medical devices [19]. - The company holds a 27.2% market share in the sodium hyaluronate-based dermal filler market by sales volume, ranking first among all manufacturers in China [24]. - The company has seen a trend of domestic products replacing imported ones in the medical beauty sector, increasing its market share [19]. - The company is positioned in the midstream of the medical beauty value chain, benefiting from the growing consumer demand for beauty services in China [19]. - The company is actively pursuing strategic acquisitions to bolster its product offerings and market share [8]. - The company is focused on international market strategies and plans to issue H-shares to access international capital markets [98]. - The company is exploring potential acquisitions to enhance its product portfolio and market presence, with discussions ongoing for two strategic targets [134]. Research and Development - The company has established several wholly-owned subsidiaries to enhance its research and development capabilities in biomedicine [6]. - The company invested 7.07% of its revenue in R&D, amounting to a 65.54% increase in R&D expenditure year-on-year [28]. - The company has accumulated 45 patents, including 25 invention patents, enhancing its competitive edge in the market [28]. - The company is conducting clinical trials for new products, including a modified hyaluronic acid gel and an injectable botulinum toxin, to enhance its product line and market position [61]. - The company aims to solidify its position in the skin filler market through new product developments and clinical trials [60]. - The company has initiated several R&D projects, including a 12,000 million RMB investment in the development of injectable type A botulinum toxin, expected to be completed by December 31, 2024 [84]. Corporate Governance and Compliance - The company has established a comprehensive governance structure, complying with relevant laws and regulations, ensuring effective internal management and control systems [103]. - The board of directors consists of 8 members, including 3 independent directors, ensuring a diverse range of expertise and compliance with legal requirements [106]. - The company has a transparent performance evaluation and incentive mechanism in place for senior management, promoting accountability and effective governance [108]. - The company emphasizes investor relations management, adhering to established protocols to maintain good communication and transparency with investors [113]. - The company operates independently from its controlling shareholders, with a complete and autonomous business operation system [114]. - The company has independent control over its assets, ensuring no guarantees or resource usage by related parties during the reporting period [115]. - The company has not engaged in any related party transactions that would compromise its financial independence [118]. - The company has maintained effective internal controls related to financial statements as of December 31, 2021 [164]. Social Responsibility and Sustainability - The company is committed to social and environmental responsibility, encouraging suppliers to obtain quality and safety certifications [170]. - The company donated 5 million RMB to support post-disaster reconstruction and mental health services in Henan after severe flooding in July 2021 [171]. - The management team emphasizes a commitment to sustainability, aiming for a 50% reduction in carbon footprint by 2025 [134]. - The company has implemented measures to ensure that emissions of pollutants comply with national and local environmental standards [166]. - The company emphasizes the protection of shareholder rights, particularly for minority shareholders, through improved governance structures [168]. Employee Management and Development - The company has established a performance management system linked to a flexible compensation system to ensure employee interests are protected [151]. - The company plans to conduct 40-50 training sessions covering all employees, utilizing both online and offline platforms [152]. - The total remuneration for directors, supervisors, and senior management in 2021 amounted to CNY 17.534 million, including CNY 560,400 paid to independent directors [139]. - The company has a structured salary system for determining the remuneration of directors and senior management, approved by the shareholders' meeting and the board of directors [139]. - The employee composition includes 236 sales personnel, 117 technical staff, 88 production workers, 49 administrative staff, and 17 finance personnel [150]. Future Outlook - The company has provided guidance for the next fiscal year, projecting a revenue growth of 25% and aiming to reach 1.875 billion RMB [134]. - New product launches are expected to contribute to growth, with three new skincare lines set to be introduced in Q2 2022 [134]. - Market expansion plans include entering two new international markets by the end of 2022, targeting a 30% increase in overseas sales [134]. - The company plans to enhance R&D investment and expand its product line in the field of biomedical materials and pharmaceuticals in 2022 [98].

Revenue and Profit - Revenue for Q3 2021 reached ¥389,636,635.96, an increase of 75.09% year-over-year, and total revenue for the year-to-date was ¥1,023,097,508.89, up 120.29% compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2021 was ¥283,441,129.32, representing a 98.01% increase year-over-year, with year-to-date net profit at ¥708,913,425.63, up 144.09%[4] - Sales revenue for the first nine months of 2021 reached CNY 1,027,185,645.09, an increase of 119.08% compared to CNY 468,861,836.99 in the same period of 2020[9] - Net profit for Q3 2021 was CNY 708,448,215.30, representing a 147.98% increase from CNY 285,689,194.18 in Q3 2020[9] - Total profit for Q3 2021 was CNY 831,172,090.87, reflecting a 149.14% increase from CNY 333,613,256.67 in Q3 2020[9] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥671,892,622.78, reflecting a significant increase of 159.67% compared to the previous year[5] - Cash flow from operating activities increased by 119.08% to CNY 1,027,185,645.09 in the first nine months of 2021[10] - Operating cash inflow for Q3 2021 was CNY 1,076,003,257.05, a significant increase from CNY 479,027,069.56 in Q3 2020, representing a growth of approximately 124.9%[25] - The company reported a net cash inflow from operating activities of CNY 671,892,622.78 for Q3 2021, compared to CNY 258,746,301.20 in Q3 2020, marking an increase of approximately 159.5%[25] Assets and Liabilities - Total assets as of September 30, 2021, were ¥4,983,968,303.65, an increase of 7.58% from the end of the previous year[5] - The company's total assets as of September 30, 2021, are 4,983,968,303.65 yuan, compared to 4,632,668,833.13 yuan at the end of 2020[18] - Total liabilities increased to CNY 199,470,415.20 from CNY 101,444,659.98, showing a growth of approximately 96% year-over-year[21] - The company’s total liabilities increased, with accounts payable recorded at CNY 4,559,011.00[29] Equity - The company's equity attributable to shareholders increased to ¥4,784,319,865.23, up 5.53% from the end of the previous year[5] - Total equity attributable to shareholders reached CNY 4,784,319,865.23, up from CNY 4,533,816,111.30, indicating an increase of about 6%[21] - The company reported an unallocated profit of 808,888,734.06, contributing to overall equity stability[30] Research and Development - R&D expenses increased by 86.50% to CNY 61,658,347.65 in Q3 2021, compared to CNY 33,060,460.35 in Q3 2020[9] - Research and development expenses for Q3 2021 totaled CNY 61,658,347.65, which is an increase from CNY 33,060,460.35 in the previous year, reflecting a growth of approximately 86%[21] Investments - Long-term equity investments surged by 2810.91% year-over-year, mainly due to investments in joint ventures during the reporting period[8] - Investment payments amounted to CNY 1,775,652,552.17, a 32.11% increase from CNY 1,344,070,800.00 in the previous year[10] - The company completed an investment of 856 million yuan in Huons Bio, acquiring a 25.42% stake as of September 30, 2021[15] Other Financial Metrics - Basic and diluted earnings per share for Q3 2021 were both ¥1.31, a decrease of 15.48% compared to the same period last year[5] - Other income increased by 269.70% to CNY 4,611,754.18, primarily due to subsidies received[9] - The company reported a significant increase in sales personnel costs, contributing to a 138.83% rise in sales expenses to CNY 100,351,573.40[9] Compliance and Reporting - The company has not reclassified any non-recurring gains and losses as recurring items, ensuring compliance with disclosure regulations[7] - The third quarter report was not audited, indicating preliminary financial data[31]

Financial Performance - The company's revenue for Q3 2021 reached ¥389,636,635.96, representing a 75.09% increase year-over-year, while total revenue for the year-to-date was ¥1,023,097,508.89, up 120.29% compared to the same period last year[3]. - Net profit attributable to shareholders for Q3 2021 was ¥283,441,129.32, an increase of 98.01% year-over-year, with a year-to-date net profit of ¥708,913,425.63, reflecting a 144.09% increase[3]. - The total revenue for the third quarter of 2021 reached 835,923,433.92, representing a 150.57% increase compared to the same period last year[8]. - Net profit for the third quarter was 708,448,215.30, reflecting a 147.98% increase year-over-year[8]. - The total profit before tax was 831,172,090.87, up 149.14% from the previous year[8]. Cash Flow and Investments - The net cash flow from operating activities for the year-to-date was ¥671,892,622.78, which is a 159.67% increase compared to the same period last year[4]. - The company reported a 119.08% increase in cash received from sales, totaling 1,027,185,645.09 for the first nine months of 2021[9]. - The company received other operating cash inflows of 44,086,479.22, a significant increase of 1105.83% year-over-year[8]. - The net cash flow from operating activities indicates a robust operational performance, supporting future growth initiatives and potential market expansion strategies[24]. - The cash inflow from operating activities was CNY 1,076,003,257.05, significantly higher than CNY 479,027,069.56 in the previous year[25]. Assets and Liabilities - Total assets as of the end of Q3 2021 amounted to ¥4,983,968,303.65, a 7.58% increase from the end of the previous year[4]. - The company's equity attributable to shareholders was ¥4,784,319,865.23, which is a 5.53% increase from the end of the previous year[4]. - The total liabilities and equity as of Q3 2021 amounted to CNY 4,983,968,303.65, up from CNY 4,632,668,833.13 in the previous year[20]. - The total liabilities included accounts payable of CNY 4,559,011.00 and contract liabilities of CNY 17,216,095.95[30]. - Total liabilities amounted to CNY 101,444,659.98, with current liabilities at CNY 89,205,738.66[31]. Expenses - Research and development expenses increased by 86.50% to 61,658,347.65, indicating a significant investment in innovation[8]. - Sales expenses surged by 138.83% to 100,351,573.40, primarily due to increased personnel costs[8]. - The company experienced a significant increase in sales expenses, which rose to CNY 100,351,573.40 from CNY 42,017,237.56, reflecting increased marketing efforts[21]. - The company experienced a decrease in cash flow due to increased operational expenses, with cash paid to employees rising to CNY 129,763,129.72 from CNY 85,777,926.49[25]. Equity and Shares - The company reported a total of 166,981,313 shares with 54,729,828 shares released from lock-up during the reporting period[13]. - The total equity attributable to shareholders of the parent company increased to CNY 4,784,319,865.23 from CNY 4,533,816,111.30 year-over-year[20]. - The company reported an unallocated profit of CNY 808,888,734.06, contributing to overall equity growth[31]. Product Development and Market Strategy - The company launched a new product, "滞白天使," which has received positive feedback and contributed to revenue during the reporting period[14][16]. - The company has established a system for doctors to apply for injection licenses, enhancing the integration of quality medical services with its products[14]. Accounting and Reporting - The company has adopted new leasing standards effective from January 1, 2021, impacting financial statements[32]. - The third quarter report was not audited, indicating preliminary financial data[32].

Financial Performance - The company achieved operating revenue of CNY 633,460,872.93, representing a 161.87% increase compared to the same period last year[14]. - The net profit attributable to shareholders reached CNY 425,472,296.31, up 188.86% year-over-year[14]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 410,883,098.52, reflecting a 191.46% increase from the previous year[14]. - The net cash flow from operating activities was CNY 437,740,198.35, an increase of 279.71% compared to the same period last year[14]. - The company's revenue for the reporting period reached ¥633,460,872.93, representing a 161.87% increase compared to ¥241,900,261.40 in the same period last year, primarily due to increased sales volume[41]. - The gross profit margin for solution injection products was 93.73%, with revenue increasing by 230.38% year-on-year, while the gross profit margin for gel injection products was 93.31%, with a 57.39% increase in revenue[43]. - The company reported a total profit of ¥497,801,109.15 for the first half of 2021, compared to ¥165,104,596.95 in the previous year, reflecting a growth of 201.5%[110]. - The total comprehensive income attributable to the parent company's owners was ¥425,472,296.31, compared to ¥147,292,865.48 in the same period of 2020, an increase of 189.5%[111]. Investments and Acquisitions - The company plans to invest approximately CNY 886 million to increase its stake in Huons BioPharma Co., Ltd. and acquire part of its equity[20]. - The company completed the acquisition of 49% equity from minority shareholders of its subsidiaries, making them wholly-owned[19]. - The company has a marketing network construction project with an investment of CNY 15,000 million, which is expected to enhance its market presence[55]. - The company has allocated CNY 50,231.00 million of unused fundraising to increase capital in its wholly-owned subsidiary, Beijing Nobot Biotechnology Co., Ltd.[56]. - The company has invested CNY 4,195.62 million of self-raised funds in fundraising projects[56]. Research and Development - The company is focused on the development of new medical materials and technologies, including 3D printing and bioengineering[8]. - The company has a strong commitment to research and development, with significant investments planned for the upcoming years[8]. - Research and development expenses amounted to ¥44,126,764.70, reflecting a 112.02% increase compared to ¥20,812,942.64 in the previous year, driven by increased R&D investments[41]. - The company registered a total of 42 patents during the reporting period, including 23 invention patents, establishing a long-term technological barrier against competitors[36]. - The company is actively involved in clinical trials for new products, including an injection of botulinum toxin and liraglutide injection, both of which are in various stages of clinical testing[31]. Market Position and Strategy - The company holds a 27.2% market share by sales volume for sodium hyaluronate injection products, ranking first in the domestic market, and a 14.3% market share by value, ranking first among domestic companies and third among all manufacturers[28]. - The company plans to expand its market presence through strategic partnerships and acquisitions[8]. - The medical beauty industry is expected to maintain high growth in the next decade, with current penetration rates in China still significantly lower than in countries like South Korea and the United States[28]. - The company has a diverse product portfolio, with seven products already on the market and several in the research and development stage, enhancing its growth potential[34]. - The company adopts a direct sales and distribution model, primarily focusing on direct sales while providing comprehensive support services to medical institutions[24]. Regulatory Compliance and Governance - The company continues to comply with regulatory requirements set by the National Medical Products Administration (NMPA)[6]. - The company has maintained its corporate governance structure without changes during the reporting period[4]. - The company has established a quality management system compliant with ISO 13485, ensuring adherence to medical device regulations and standards[22]. - The company has a dedicated team for investor relations to ensure transparent communication with stakeholders[9]. - The company has not engaged in any major related party transactions during the reporting period[82]. Financial Position and Assets - Total assets at the end of the reporting period were CNY 4,670,898,180.09, a 0.83% increase from the end of the previous year[14]. - Cash and cash equivalents at the end of the reporting period amounted to ¥3,430,034,670.24, accounting for 73.43% of total assets, a decrease of 1.17% compared to the previous year[46]. - Accounts receivable increased to ¥39,124,173.26, representing 0.84% of total assets, up by 0.20% due to increased sales during the reporting period[46]. - Long-term equity investments rose significantly to ¥132,188,072.74, making up 2.83% of total assets, an increase of 2.10% attributed to external equity investments[46]. - The company reported a total liability of CNY 169,723,946.39, compared to CNY 99,934,977.51, reflecting a growth of 69.5%[108]. Risks and Challenges - The company is actively monitoring potential risks and has outlined measures to mitigate them[3]. - The company faces risks related to industry policy changes, which could impact its operational plans, particularly in the medical device sector[65]. - The competitive landscape in the medical beauty market is intensifying, with many companies entering the sector through R&D and mergers[67]. - The company is focused on continuous improvement and innovation in product development to address the risks associated with R&D and registration processes[66]. Shareholder Information - The total number of shares increased from 120,200,000 to 216,360,000 due to a capital reserve conversion, resulting in an increase of 96,160,000 shares[91]. - The basic earnings per share (EPS) for the first half of 2021 was 1.97 CNY, calculated based on the post-conversion total shares[91]. - The diluted EPS for the same period was also 1.97 CNY, reflecting the impact of the increased share count[91]. - The company distributed 96,160,000 shares to all shareholders at a ratio of 8 shares for every 10 shares held[91]. - The largest shareholder, Jian Jun, holds 30.96% of shares, totaling 66,988,343 shares, with an increase of 29,772,597 shares during the reporting period[97].